Free Trial

Co-Diagnostics Q1 2024 Earnings Report

Co-Diagnostics logo
$0.75 -0.04 (-4.94%)
As of 01/31/2025 04:00 PM Eastern

Co-Diagnostics EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.21
Beat/Miss
Missed by -$0.10
One Year Ago EPS
-$0.20

Co-Diagnostics Revenue Results

Actual Revenue
$0.47 million
Expected Revenue
$3.10 million
Beat/Miss
Missed by -$2.63 million
YoY Revenue Growth
N/A

Co-Diagnostics Announcement Details

Quarter
Q1 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Co-Diagnostics Earnings Headlines

Unveiling 7 High-Potential Stocks for 2025
Welcome to 2025—a year brimming with exceptional investment possibilities! Our comprehensive guide, "7 Stocks Set to Soar," has been carefully curated to help you enhance your portfolio this year. Stay Ahead with Cutting-Edge Trends This year, advancements in artificial intelligence are driving transformative changes across various sectors. From AI-powered healthcare innovations to intelligent automation in manufacturing, these technological breakthroughs are creating fertile ground for select companies to thrive. Our guide delves into how these trends are shaping the future and spotlighting the stocks positioned to capitalize on them.
Co-Diagnostics Reports Q3 2024 Financial Results
See More Co-Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email.

About Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

View Co-Diagnostics Profile

More Earnings Resources from MarketBeat